Investigating genetic factors affecting diabetes treatment response

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study examines how genetic variations influence the effectiveness of exenatide, a GLP-1 receptor agonist, in treating Type 2 Diabetes Mellitus (T2DM) among Chinese patients. It involves a retrospective cohort of patients who have been treated with exenatide for at least 12 months, analyzing various gene polymorphisms associated with T2DM susceptibility. The goal is to identify predictors of treatment efficacy and understand the genetic determinants that contribute to individual differences in response to antidiabetic medications. This research aims to enhance personalized treatment strategies for T2DM patients based on their genetic profiles.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. a diagnosis of T2DM
2. a body mass index (BMI) of 20-35 kg/m2
3. an HbA1c of 7.0%-12%, an age of 25-70 years
4. required data available at baseline and 6 months after GLP-1RA therapy.

Exclusion Criteria:

1. Patients with serious diseases such as acute myocardial infarction, cerebral vascular accident, trauma, kidney or liver diseases, severe gastrointestinal dysfunction, and history of pancreatitis
2. patients receiving GLP-1 analogues, weight loss drugs, glucocorticoids, drugs affecting gastrointestinal peristalsis in the past 3 months
3. those with missing data at the time points of baseline, 3 months, and 6 months after GLP-1 RA therapy.

Where it's running

• China, Jiangsu, Department of Endocrinology
  Xuzhou, China, China Recruiting

Study contacts

• Study coordinator: Tao Wang, Ph.D
• Email: misswt2011@126.com
• Phone: 13815344640

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating how gene mutations affect diabetes susceptibility in patients

  This study is testing how certain gene changes might affect the risk of developing Type 2 Diabetes in newly diagnosed patients compared to healthy individuals.

  Recruiting The Affiliated Hospital of Xuzhou Medical University · Xuzhou · NCT06277466

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Acupuncture plus vitamin B12 for diabetic heart nerve damage

  This study tests whether adding acupuncture to standard care and vitamin B12 can help adults with type 2 diabetes who have damaged the nerves that control the heart.

  Recruiting The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07907536

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Body composition changes after starting GLP-1 therapies in adults with obesity or type 2 diabetes

  This study will follow adults with obesity and/or type 2 diabetes who are starting or adjusting a GLP-1 receptor agonist to see how their muscle and fat change over about a year.

  Recruiting at 2 sites Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Mexico City, Mexico City and 1 other locations · NCT07835360

• Single-dose PK study of HRS-4729 in adults with and without kidney impairment

  This study tests a single dose of HRS-4729 to see how the body handles it in adults with various levels of kidney function compared with healthy adults.

  Recruiting Phase 1 Fujian Shengdi Pharmaceutical Co., Ltd. · Chengdu, Sichuan · NCT07807059

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.